HLA-haploidentical stem cell transplantation for hematologic malignancies.

Ephraim J Fuchs, Xiao jun Huang, Jeffrey S. Miller

Research output: Contribution to journalArticle

Abstract

Partially HLA-mismatched related, or HLA-haploidentical, donor stem cell transplantation (SCT) is a feasible therapeutic option for advanced hematologic malignancies patients who lack an HLA-matched related or unrelated donor. Advances in conditioning regimens, graft manipulation, and pharmacologic prophylaxis of graft-versus-host disease (GVHD) have reduced the risk of fatal graft failure and severe GVHD, two of the most serious complications of traversing the HLA barrier. Clinical observations reveal a potential role for natural killer (NK) cell alloreactivity in reducing the risk of relapse of acute myeloid leukemia after HLA-haploidentical SCT. NK cell infusions attempt to harness the graft-versus-leukemia effect without producing GVHD. The availability of multiple potential HLA-haploidentical related donors for most patients opens the possibility of optimizing transplantation outcome through intelligent donor selection.

Original languageEnglish (US)
JournalBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Volume16
Issue number1 Suppl
StatePublished - Jan 2010

Fingerprint

Stem Cell Transplantation
Graft vs Host Disease
Hematologic Neoplasms
Transplants
Natural Killer Cells
Tissue Donors
Donor Selection
Unrelated Donors
Acute Myeloid Leukemia
Leukemia
Transplantation
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{ef3965531c91438bba966a94b3d36bd3,
title = "HLA-haploidentical stem cell transplantation for hematologic malignancies.",
abstract = "Partially HLA-mismatched related, or HLA-haploidentical, donor stem cell transplantation (SCT) is a feasible therapeutic option for advanced hematologic malignancies patients who lack an HLA-matched related or unrelated donor. Advances in conditioning regimens, graft manipulation, and pharmacologic prophylaxis of graft-versus-host disease (GVHD) have reduced the risk of fatal graft failure and severe GVHD, two of the most serious complications of traversing the HLA barrier. Clinical observations reveal a potential role for natural killer (NK) cell alloreactivity in reducing the risk of relapse of acute myeloid leukemia after HLA-haploidentical SCT. NK cell infusions attempt to harness the graft-versus-leukemia effect without producing GVHD. The availability of multiple potential HLA-haploidentical related donors for most patients opens the possibility of optimizing transplantation outcome through intelligent donor selection.",
author = "Fuchs, {Ephraim J} and Huang, {Xiao jun} and Miller, {Jeffrey S.}",
year = "2010",
month = "1",
language = "English (US)",
volume = "16",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "1 Suppl",

}

TY - JOUR

T1 - HLA-haploidentical stem cell transplantation for hematologic malignancies.

AU - Fuchs, Ephraim J

AU - Huang, Xiao jun

AU - Miller, Jeffrey S.

PY - 2010/1

Y1 - 2010/1

N2 - Partially HLA-mismatched related, or HLA-haploidentical, donor stem cell transplantation (SCT) is a feasible therapeutic option for advanced hematologic malignancies patients who lack an HLA-matched related or unrelated donor. Advances in conditioning regimens, graft manipulation, and pharmacologic prophylaxis of graft-versus-host disease (GVHD) have reduced the risk of fatal graft failure and severe GVHD, two of the most serious complications of traversing the HLA barrier. Clinical observations reveal a potential role for natural killer (NK) cell alloreactivity in reducing the risk of relapse of acute myeloid leukemia after HLA-haploidentical SCT. NK cell infusions attempt to harness the graft-versus-leukemia effect without producing GVHD. The availability of multiple potential HLA-haploidentical related donors for most patients opens the possibility of optimizing transplantation outcome through intelligent donor selection.

AB - Partially HLA-mismatched related, or HLA-haploidentical, donor stem cell transplantation (SCT) is a feasible therapeutic option for advanced hematologic malignancies patients who lack an HLA-matched related or unrelated donor. Advances in conditioning regimens, graft manipulation, and pharmacologic prophylaxis of graft-versus-host disease (GVHD) have reduced the risk of fatal graft failure and severe GVHD, two of the most serious complications of traversing the HLA barrier. Clinical observations reveal a potential role for natural killer (NK) cell alloreactivity in reducing the risk of relapse of acute myeloid leukemia after HLA-haploidentical SCT. NK cell infusions attempt to harness the graft-versus-leukemia effect without producing GVHD. The availability of multiple potential HLA-haploidentical related donors for most patients opens the possibility of optimizing transplantation outcome through intelligent donor selection.

UR - http://www.scopus.com/inward/record.url?scp=77953074172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953074172&partnerID=8YFLogxK

M3 - Article

C2 - 19892024

AN - SCOPUS:77953074172

VL - 16

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 1 Suppl

ER -